| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
| Products Intro: |
Product Name:Bifeprunox CAS:350992-10-8 Purity:95% Remarks:Reach out to us for more information about custom solutions.
|
7-[4-[(3-phenylphenyl)methyl]piperazin-1-yl]-3H-benzooxazol-2-one manufacturers
- Bifeprunox
-
- $2500.00 / 100mg
-
2025-07-23
- CAS:350992-10-8
- Min. Order:
- Purity:
- Supply Ability: 10g
- Bifeprunox
-
- $2500.00 / 100mg
-
2025-07-18
- CAS:350992-10-8
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | 7-[4-[(3-phenylphenyl)methyl]piperazin-1-yl]-3H-benzooxazol-2-one Basic information |
| Product Name: | 7-[4-[(3-phenylphenyl)methyl]piperazin-1-yl]-3H-benzooxazol-2-one | | Synonyms: | 7-[4-[(3-phenylphenyl)methyl]piperazin-1-yl]-3H-benzooxazol-2-one;Bifeprunox;7-(4-([1,1,-biphenyl]-3-ylmethyl)piperazin-1-yl)benzo[d]oxazol-2(3H)-one;7-[4-[(3-phenylphenyl)methyl]-1-piperazinyl]-3H-1,3-benzoxazol-2-one;2(3H)-Benzoxazolone, 7-[4-([1,1'-biphenyl]-3-ylmethyl)-1-piperazinyl]- | | CAS: | 350992-10-8 | | MF: | C24H23N3O2 | | MW: | 385.46 | | EINECS: | | | Product Categories: | | | Mol File: | 350992-10-8.mol | ![7-[4-[(3-phenylphenyl)methyl]piperazin-1-yl]-3H-benzooxazol-2-one Structure](CAS/GIF/350992-10-8.gif) |
| | 7-[4-[(3-phenylphenyl)methyl]piperazin-1-yl]-3H-benzooxazol-2-one Chemical Properties |
| | 7-[4-[(3-phenylphenyl)methyl]piperazin-1-yl]-3H-benzooxazol-2-one Usage And Synthesis |
| Uses | Acute schizophrenia. | | Definition | ChEBI: Bifeprunox is a member of biphenyls. | | in vivo | Bifeprunox (0.001-2.5 mg/kg) reduces marble burying in mice[2].
Bifeprunox (4-250 μg/kg) influences nicotine-seeking behaviour in response to drug-associated stimuli in rats[3]. | Animal Model: | Male NMRI mice (weighing 20-22 g)[2] | | Dosage: | 0.001, 0.0025, 0.01, 0.04, 0.16, 0.63, and 2.5 mg/kg | | Administration: | I.p. | | Result: | Reduced marble burying. Potently active from 0.0025 mg/kg. |
| Animal Model: | Na?ve male Wistar rats (weighing 250-275 g)[3] | | Dosage: | 4, 16, 64 and 250 μg/kg | | Administration: | Injected s.c. 30 minutes before testing | | Result: | 4-16 μg/kg dose-dependently attenuated the responsereinstating effects of nicotine-associated cues. Higher doses (64-250 μg/kg, s.c.) reduced spontaneous locomotor activity and suppressed operant responding induced by sucrose-associated cues and by the primary reinforcing properties of nicotine or sucrose. |
| | IC 50 | 5-HT1A Receptor: 7.19 (pKi, cortex); D2 Receptor: 8.83 (pKi, striatum); 5-HT1A Receptor: 6.37 (pEC50, hippocampus) |
| | 7-[4-[(3-phenylphenyl)methyl]piperazin-1-yl]-3H-benzooxazol-2-one Preparation Products And Raw materials |
|